Abstract
CpG-DNA activates various immune cells, contributing to the host defense against bacteria. Here, we examined the biological function of CpG-DNA in the production of bacteria-reactive antibodies. The administration of CpG-DNA increased survival in mice following infection with methicillin-resistant S. aureus and protected immune cell populations in the peritoneal cavity, bone marrow, and spleen. CpG-DNA injection likewise increased bacteria-reactive antibodies in the mouse peritoneal fluid and serum, which was dependent on TLR9. B cells isolated from the peritoneal cavity produced bacteria-reactive antibodies in vitro following CpG-DNA administration that enhanced the phagocytic activity of the peritoneal cells. The bacteria-reactive monoclonal antibody enhanced phagocytosis in vitro and protected mice after S. aureus infection. Therefore, we suggest that CpG-DNA enhances the antibacterial activity of the immune system by protecting immune cells and triggering the production of bacteria-reactive antibodies. Consequently, we believe that monoclonal antibodies could aid in the treatment of antibiotic-resistant bacterial infections.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adjuvants, Immunologic / administration & dosage*
-
Animals
-
Antibodies, Bacterial / blood
-
Antibodies, Bacterial / immunology
-
Antibodies, Bacterial / metabolism
-
Antibodies, Monoclonal / blood
-
Antibodies, Monoclonal / immunology
-
Antibodies, Monoclonal / metabolism
-
Antibody Formation / drug effects
-
B-Lymphocytes / drug effects
-
B-Lymphocytes / immunology
-
B-Lymphocytes / metabolism
-
Disease Models, Animal
-
Female
-
Humans
-
Injections, Intraperitoneal
-
Methicillin-Resistant Staphylococcus aureus / immunology*
-
Mice
-
Mice, Inbred BALB C
-
Mice, Knockout
-
Oligodeoxyribonucleotides / administration & dosage*
-
Phagocytosis / drug effects
-
Phagocytosis / immunology
-
Staphylococcal Infections / blood
-
Staphylococcal Infections / immunology
-
Staphylococcal Infections / microbiology
-
Staphylococcal Infections / therapy*
-
Toll-Like Receptor 9 / genetics
-
Toll-Like Receptor 9 / immunology
-
Toll-Like Receptor 9 / metabolism
-
Treatment Outcome
Substances
-
Adjuvants, Immunologic
-
Antibodies, Bacterial
-
Antibodies, Monoclonal
-
CPG-oligonucleotide
-
Oligodeoxyribonucleotides
-
Tlr9 protein, mouse
-
Toll-Like Receptor 9